Teva Pharmaceutical Industries Ltd (TEVA)

[genisi]

PreCISe data published in the Lancet

http://podcast.thelancet.com/audio/lancet/2009/07october.mp3

PreCISe study and multiple sclerosis

Encouraging results from a phase III placebo-controlled trial suggest that glatiramer acetate (already licensed for relapsing-remitting multiple sclerosis) is effective in reducing progression to clinically definite disease after a first clinically isolated syndrome. Individuals were studied for three years, with MRI analysis done every 3 months to compare underlying disease progression with clinical symptoms. The study is discussed in a podcast.

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61259-9/fulltext